Welcome to SBS 2011 - SLAS

Gaylord Palms Resort and Convention Center | March 27–31, 2011 | Orlando, Florida, USA
3:30 – 4:00 pm Page 41
4:00 – 4:30 pm Page 41
1:30 – 4:30 pm Osceola B
1:30 – 2:00 pm Page 43
2:00 – 2:30 pm Page 43
3:00 – 3:30 pm Page 43
3:30 – 4:00 pm Page 44
4:00 - 4:30 pm Page 44
Tuesday, March 29
9:00 am – 12:00 pm Osceola A
9:00 – 9:30 am Page 46
9:30 – 10:00 am Page 46
10:30 – 11:00 am Page 46
11:00 – 11:30 am Page 47
11:30 am – 12:00 pm Page 47
Challenges and Successes of Translational Research in the Public Domain:
Retrospective and Prospective Analyses and Case Histories of “Probes to
Leads” From Six Years of the Molecular Libraries Program; Thomas “T.C.”
Chung, Conrad Prebys Center for Chemical Genomics at Sanford-Burnham
Medical Research Institute
Translation in Action: MRCT's Centre for Therapeutics Discovery;
Justin Bryans, MRC Technology
Track III » Session 1: Target Resuscitation:
Drug Repositioning Opportunities
Session Chair: Roger Bosse, PerkinElmer
Plenary: Drug Repositioning: How it Fits With Current Drug-Discovery
Trends; Christopher A. Lipinski, Melior Discovery
Prodrugs: Regulatory and Clinical Development Requirements For Approval;
Ken Phelps, Camargo Pharmaceutical Services, LLC
Exploring Ligand-Directed Functional Selectivity of GPCR With Bret-Based
Biosensor Arrays and Label-Free Impedance Measurements; Linking
Signaling Signature to Drug Efficacy; Michel Bouvier, Drug Discovery Group,
University of Montreal
A Rapid Assay for Identifying New Drug Candidates From Approved
Drugs for Repositioning to Treat Giardiasis; Catherine Chen, NIH Chemical
Genomics Center
HTS for REST Inhibitors in Neural Progenies of Human ES Cells;
Anselme Perrier, I-Stem
Track I » Session 2: Innovations in Screening Biology:
Assays, Techniques and Instrumentation
Session Chair: Jonathan O’Connell, Bristol-Myers Squibb Company
Plenary: The Evolution of HTS at Bristol-Myers Squibb: Enabling
the Support of the Most Relevant Bio-Assays; Jonathan O’Connell,
Bristol-Myers Squibb Company
Etv6-NTRK3, A Constitutively Active Tyrosine Kinase Found in Variety
of Tumors, is Unique in its Mechanism of Transformation;
Jack Allen, Merrimack Pharmaceuticals
High-Throughput Screening With Real-Time PCR: Reducing it to Practice;
Andrea Weston, Bristol-Myers Squibb Company
New Ion Channel Screening Technologies Enabling Development of High
Quality and High-Throughput Assays in a Plate-Based Screening Group;
Juha Kammonen, Pfizer
Creating a Holistic Screening Strategy for Label-Free Technology in a Plate
Based Screening Group; Rachel Russell, Pfizer Global Research & Development
SLAS.org/events/sbs11 | 31